Safety and Efficacy of AT-1501 in Patients with IgAN
Research type
Research Study
Full title
A Phase 2a, Multicenter, Open-Label Study to Evaluate the Safety and Efficacy of AT-1501 in Patients with IgA Nephropathy
IRAS ID
308255
Contact name
Jennifer Bartoshevich
Contact email
Sponsor organisation
Eledon Pharmaceuticals, Inc
Eudract number
2021-004795-34
Clinicaltrials.gov Identifier
Duration of Study in the UK
3 years, 3 months, 6 days
Research summary
The reason for conducting this study is to investigate whether inhibition of CD40LG with AT-1501 and its downstream effects on inflammation will have an impact on urine protein loss over a 6-month period. Improvement in the loss of protein has been demonstrated to be a surrogate that is reasonably likely to predict a slowing in the loss of renal function.
REC name
South Central - Berkshire B Research Ethics Committee
REC reference
22/SC/0028
Date of REC Opinion
23 Mar 2022
REC opinion
Further Information Favourable Opinion